文献速递淋巴瘤

复发/难治性大B细胞淋巴瘤CAR-T失败后双特异性抗体治疗的结局

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

这项多中心回顾性分析纳入92例CAR-T失败后接受双特异性抗体治疗的复发/难治性大B细胞淋巴瘤患者,总缓解率43%,无进展生存期2.8个月;早期复发(≤3个月)患者结局显著更差,ORR 29%、PFS 2.2个月,而中期(4-6个月)和晚期(>6个月)复发患者ORR分别为54%和60%、PFS分别为3.7和10.5个月。

要点

  • CAR-T失败后BsAb治疗ORR 43%,PFS 2.8个月。
  • 早期复发(≤3个月)患者ORR 29%、PFS 2.2个月,结局显著更差。
  • 晚期复发患者以BsAb为首个挽救治疗时PFS和OS均未达到。

核心结论

  • CAR-T后早期复发患者对BsAb应答尤其差,凸显该高危人群需要替代治疗选择。

研究设计与样本

  • 多中心回顾性分析,纳入92例CAR-T失败后接受双特异性抗体治疗的复发/难治性大B细胞淋巴瘤患者。

主要发现

  • 总体缓解率43%,无进展生存期2.8个月。
  • 早期复发(≤3个月)患者ORR 29%、PFS 2.2个月,显著差于中期复发(4-6个月;ORR 54%、PFS 3.7个月)和晚期复发(>6个月;ORR 60%、PFS 10.5个月)患者。
  • 晚期复发患者以BsAb作为首个挽救治疗对比后续线数BsAb:PFS未达到 vs 2.7个月,OS未达到 vs 9.1个月。
  • 多因素Cox回归分析中,BsAb前早期复发/难治状态、乳酸脱氢酶升高和国际预后指数评分较高是BsAb不良结局的显著预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% of these cases. Hypothesizing overlapping LBCL-intrinsic resistance mechanisms as well as common poor prognosis predictors to CAR-T and BsAb therapy, we conducted a multicenter retrospective analysis including 92 patients with relapsed/refractory (R/R) LBCL treated with BsAbs after CAR-T failure. Overall response rate (ORR) was 43%, with a progression-free survival (PFS) of 2.8 months. Patients receiving BsAbs during early relapse (≤3 months) achieved a significantly worse outcome (ORR, 29%; PFS, 2.2 months) compared with patients with an intermediate (4-6 months; ORR, 54%; PFS, 3.7 months) or a late relapse (>6 months; ORR, 60%; PFS, 10.5 months). The benefit of later relapse was particularly notable in patients receiving BsAbs as first salvage therapy compared with those receiving a BsAb in subsequent lines (PFS not reached vs 2.7 months; overall survival not reached vs 9.1 months, respectively). In addition to early R/R state before BsAbs, elevated lactate dehydrogenase and higher International Prognostic Index score were significant predictors of poor outcomes to BsAb in multivariate Cox regression analyses. The finding that patients with early relapse after CAR-T respond particularly poorly to BsAb highlights the necessity for alternative treatment options in this high-risk patient cohort.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shumilov E, Scholz JK, Seib M, et al. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma. Blood Adv. 2025. PMID: 40238938. doi:10.1182/bloodadvances.2024015719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。